Emergent Biosolutions is a drug manufacturers - specialty & generic business based in the US. Emergent Biosolutions shares (EBS) are listed on the NYSE and all prices are listed in US Dollars. Emergent Biosolutions employs 1,600 staff and has a trailing 12-month revenue of around $1.2 billion.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $13.80 |
|---|---|
| 52-week range | $1.42 - $12.74 |
| 50-day moving average | $6.94 |
| 200-day moving average | $3.47 |
| Wall St. target price | $8.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-10.97 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $13.8 from 2024-07-25
| 1 week (2024-07-19) | 23.21% |
|---|---|
| 1 month (2024-06-26) | 110.37% |
| 3 months (2024-04-26) | 618.75% |
| 6 months (2024-01-26) | 658.24% |
| 1 year (2023-07-26) | 92.74% |
|---|---|
| 2 years (2022-07-26) | -59.87% |
| 3 years (2021-07-26) | 62.37 |
| 5 years (2019-07-26) | 44.41 |
Valuing Emergent Biosolutions stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Emergent Biosolutions's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Emergent Biosolutions's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.55. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Emergent Biosolutions's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Emergent Biosolutions's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $100.2 million.
The EBITDA is a measure of a Emergent Biosolutions's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $1.2 billion |
|---|---|
| Operating margin TTM | 13.25% |
| Gross profit TTM | $290.1 million |
| Return on assets TTM | -0.38% |
| Return on equity TTM | -60.57% |
| Profit margin | -47.69% |
| Book value | $12.67 |
| Market Capitalization | $586.9 million |
TTM: trailing 12 months
We're not expecting Emergent Biosolutions to pay a dividend over the next 12 months.
Over the last 12 months, Emergent Biosolutions's shares have ranged in value from as little as $1.42 up to $12.74. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Emergent Biosolutions's is 1.621. This would suggest that Emergent Biosolutions's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Emergent BioSolutions Inc. , a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Steps to owning and managing ZTEK, with 24-hour and historical pricing before you buy.
Steps to owning and managing MYNZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing ATAI, with 24-hour and historical pricing before you buy.
Steps to owning and managing OWLT, with 24-hour and historical pricing before you buy.
Steps to owning and managing LLY, with 24-hour and historical pricing before you buy.
Steps to owning and managing HUM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ILMN, with 24-hour and historical pricing before you buy.
Steps to owning and managing UNH, with 24-hour and historical pricing before you buy.
Steps to owning and managing PFE, with 24-hour and historical pricing before you buy.
Steps to owning and managing JNJ, with 24-hour and historical pricing before you buy.